ICU Girisim Sermayesi Yatirim Ortakligi A.S.

As of June 30, 2025, ICU Girisim Sermayesi Yatirim Ortakligi A.S. carries a market capitalization of 1.01B, placing it among publicly traded companies globally. Its enterprise value stands at 1.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2025, ICU Girisim Sermayesi Yatirim Ortakligi A.S. has 347.50M shares outstanding.

As of June 30, 2025, ICU Girisim Sermayesi Yatirim Ortakligi A.S. trades at a trailing price-to-earnings ratio of 11.10.

As of June 30, 2025, ICU Girisim Sermayesi Yatirim Ortakligi A.S. trades at an EV/EBITDA multiple of 5.83 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.84 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. ICU Girisim Sermayesi Yatirim Ortakligi A.S. trades at an EV/FCF ratio of 6.42, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.01B versus a market cap of 1.01B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2025.

These figures cover the twelve months ended June 30, 2025. The company generates approximately 18.05M in revenue per employee across its workforce of 10.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2025, ICU Girisim Sermayesi Yatirim Ortakligi A.S. recorded 5.20M in income tax expense. That works out to an effective tax rate of 5.40, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 96.30M, leaving 91.10M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, ICU Girisim Sermayesi Yatirim Ortakligi A.S.'s stock has declined approximately 64.56% over the past 52 weeks. The 50-day moving average sits at 3.04, while the 200-day moving average is 4.03.

Over the twelve months ended June 30, 2025, ICU Girisim Sermayesi Yatirim Ortakligi A.S. generated 189.57M in revenue and converted that into 91.10M in net income, yielding earnings per share of 0.26. EBITDA reached 173.40M, while operating income came in at 127.94M.

ICU Girisim Sermayesi Yatirim Ortakligi A.S. produced 157.35M in operating cash flow over the twelve months ended June 30, 2025. After subtracting -76,687.00 in capital expenditures, free cash flow totaled 157.28M - equivalent to 0.45 per share.

These figures cover the twelve months ended June 30, 2025. The operating margin of 67.49 and net profit margin of 48.06 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Free cash flow yield stands at 15.55, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.06, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ICU Girisim Sermayesi Yatirim Ortakligi A.S. shareholders.

ICU Girisim Sermayesi Yatirim Ortakligi A.S.'s most recent stock split took place on June 16, 2025 with a 1:5 split ratio.